Home > COX & > Piroxicam

Piroxicam

吡罗昔康,CP 16171,Feldene,CP-16171,CP16171,

Piroxicam是非选择性COX抑制剂,IC50为6 mM。

目录号
EY0631
EY0631
EY0631
纯度
99.54%
99.54%
99.54%
规格
500 mg
1 g
5 g
原价
370
485
880
售价
370
485
880
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
  • 生物活性

    Piroxicam is a non-selective COX inhibitor, used in the treatment of rheumatoid and osteoarthritis.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 AKm系数


    例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。


  • 参考文献

    [1] Vartiainen N, et al. J Neurochem,2001, 76(2), 480-489.
    [2] Laneuville, O., et al. 1994. J. Pharmacol. Exp. Ther. 271: 927-934.

    分子式
    C15H13N3O4S
    分子量
    331.35
    CAS号
    36322-90-4
    储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂(常温)
    DMSO
    25 mg/mL
    Water
    <1 mg/mL
    Ethanol
    5 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT02253446 Primary Dysmenorrhea Drug: Piroxicam|Drug: Diclofenac Sodium Pamukkale University Phase 4 2013-05-01 2014-09-27
    NCT00670475 Osteoarthritis of the Knee Drug: Piroxicam|Dietary Supplement: Olive Oil Ardabil University of Medical Sciences Phase 2 2008-04-01 2010-04-28
    NCT03006107 Pulpitis - Irreversible Procedure: intraligamentary injection piroxicam|Procedure: Intraligamentary mepevacaine Cairo University 2016-12-01 2016-12-27
    NCT01320709 Contraception, Postcoital Drug: Piroxicam ( BAYl1902)|Drug: Piroxicam ( BAYl1902)|Drug: Placebo|Drug: Piroxicam ( BAYl1902) Bayer Phase 2 2011-03-01 2015-07-09
    NCT00649415 Dysmenorrhea Drug: piroxicam|Drug: valdecoxib Pfizer Phase 4 2003-01-01 2008-04-07
    NCT02304783 Renal Colic Drug: Piroxicam|Drug: Placebo University of Monastir Phase 1|Phase 2 2014-01-01 2016-04-01
    NCT02382653 Neoplasm Metastases Drug: oral perixicam Tanta University 2014-12-01 2016-05-11
    NCT00631514 Hypertension Drug: acetaminophen|Drug: ibuprofen|Drug: piroxicam University of Split|Dr Ivancica Pavlicevic Family Practice Office Phase 4 2005-01-01 2008-03-07
    NCT01480752 Post Operative Endodontic Pain Drug: Lornoxicam|Drug: normal saline|Drug: no injection Islamic Azad University, Tehran Phase 2 2011-09-01 2013-01-11
    NCT00997750 Acute Coronary Syndrome Drug: Lornoxicam Central Clinical Hospital with Outpatient Health Center of Business Administration for the President of Russian Federati Phase 4 2007-03-01 2009-10-18
    NCT00293657 Headache (Migraine) Drug: Lornoxicam 8 mg|Drug: Lornoxicam 16 mg|Drug: Placebo POZEN Phase 2 2005-12-01 2012-11-29
    NCT02750917 Postoperative Pain Drug: Lornoxicam|Drug: Etoricoxib Foisor Orthopedics Clinical Hospital Phase 3 2014-09-01 2016-04-25
    NCT01564680 Postoperative Pain Other: placebo|Drug: Paracetamol|Drug: Lornoxicam Dammam University Phase 4 2009-03-01 2012-03-27
    NCT01069055 Inguinal Hernia|Postoperative Pain Other: Sterile Saline|Drug: Intravenous lornoxicam|Drug: Intravenous paracetamol Diskapi Teaching and Research Hospital Phase 3 2010-02-01 2010-02-23
    NCT01055470 Osteoarthritis of Knee Joint Drug: Diclofenac|Drug: Lornoxicam Government Medical College, Bhavnagar 2008-12-01 2010-01-22
    NCT00530387 Dermatitis, Photocontact Drug: 19 organic sunscreen filters and 5 topical NSAIDs NHS Tayside 2008-07-01 2011-08-03
    NCT02549118 Analgesia|Obstetrical Drug: Tenoxicam|Drug: Pethidine Ain Shams Maternity Hospital Phase 2 2015-09-01 2015-09-11
    NCT02025166 Pain Drug: Paracetamol|Drug: lornoxicam Rambam Health Care Campus 2014-01-01 2013-12-30
    NCT01718756 Closed Non Comminuted Long Bone Fractures Drug: Placebo|Drug: Continuous infusion|Drug: Scheduled Mansoura University Phase 1|Phase 2 2013-06-01 2015-03-15
    NCT00293631 Bunionectomy|Orthopedic Surgery Drug: Lornoxicam 8 mg|Drug: Lornoxicam 16 mg|Drug: Ketorolac 30 mg|Drug: Placebo POZEN Phase 2 2005-11-01 2012-11-29
    NCT02191358 Adverse Drug Events|Adverse Drug Reactions|Drug Interaction Potentiation|Drug Metabolism, Poor, CYP2D6-RELATED|Drug Metabolism, Poor, CYP2C19-RELATED|Cytochrome P450 Enzyme Deficiency|Cytochrome P450 CYP2D6 Enzyme Deficiency|Cytochrome P450 CYP2C9 Enzyme Deficiency|Cytochrome P450 CYP2C19 Enzyme Deficiency|Cytochrome P450 CYP3A Enzyme Deficiency|Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant|Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant|Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant Genelex Corporation|University of Utah 2014-10-01 2017-02-27
    NCT03038321 Non-Muscle-invasive Bladder Cancer (NMIBC)|Bacillus Calmette-Guerin (BCG) Cystitis|Intra-vesical Instillation Drug: sofenacin|Drug: Tavanic|Drug: Xefo Mansoura University Phase 4 2017-02-01 2017-03-20
    NCT02160236 Postoperative Pain Drug: dexketoprofen trometamol|Drug: tenoxicam|Drug: serum physiologic TC Erciyes University Phase 4 2014-11-01 2014-11-07

    注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 :
  • 收件地址 :
  • 电话号码 :
  • 单位名称 :
  • 产品货号 :
  • 产品规格 :
  • 发票抬头以及单位税号 :